Author

F. Shah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:software / tool· 1

Frequent Co-Authors

B. Park· 1 shared C. Grek· 1 shared D. Kelly· 1 shared G. Ghatnekar· 1 shared G. Lewis· 1 shared J. H. Wikel· 1 shared J. Herisson· 1 shared J. Jourdan· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

B. Park

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Connexin 43 confers chemoresistance through activating PI3K

K. Pridham, F. Shah, K. Sheng, S. Guo, M. Liu, P. Kanabur, S. Lamouille, G. Lewis, M. Morales, J. Jourdan, C. Grek, G. Ghatnekar, R. Varghese, D. Kelly, R. G. Gourdie, Z. Sheng

This study identifies Cx43's role in glioblastoma chemoresistance by activating PI3K signaling, and shows that targeting Cx43 and PI3K{beta} restores temozolomide sensitivity.

bioRxiv · Oct 14, 2020Cancer Biology

Galaxy-SynBioCAD: Synthetic Biology Design Automation tools in Galaxy workflows

M. du Lac, T. Duigou, J. Herisson, P. Carbonell, N. Swainston, V. Zulkower, F. Shah, L. Faure, M. Mahdy, P. Soudier, J.-L. Faulon

Galaxy-SynBioCAD provides a workflow platform for synthetic biology design, enabling compatible tools and workflows to automate metabolic pathway design with 65% success in retrieving literature pathways.

bioRxiv · Jun 14, 2020 · PreprintBioengineering

Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization

S. P. Sheik Pran Babu, K. Sishtla, R. S. Sulaiman, B. Park, T. Shetty, F. Shah, M. L. Fishel, J. H. Wikel, M. R. Kelley, T. W. Corson

This paper develops and tests new Ref-1/APE1 inhibitors, showing they block ocular neovascularization in vitro, ex vivo, and in a mouse model.

bioRxiv · Jun 23, 2018Pharmacology & Toxicology